Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ISRCTN97337444) titled 'Phase I study of PM534 to patients with advanced solid tumors' on May 20.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: To identify the dose-limiting toxicities (DLTs), and to determine the maximum tolerated dose (MTD) and the recommended dose (RD) and to evaluate the antitumor activity in solid tumors
Primary Sponsor: PharmaMar (Spain)
Condition:
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Other
Interve...